Table 1 Patient baseline characteristics
Characteristics | 1 L (n = 62) | 2 L (n = 20) |
|---|---|---|
Age, n (%) | ||
< 65 years | 37 (59.7) | 7 (35.0) |
≥ 65 years | 25 (40.3) | 13 (65.0) |
Median age (range), years | 62 (36–85) | 69 (30–80) |
Sex, n (%) | ||
Male | 43 (69.4) | 15 (75.0) |
Female | 19 (30.6) | 5 (25.0) |
ECOG PS, n (%) | ||
0 | 37 (59.7) | 9 (45.0) |
1 | 25 (40.3) | 11 (55.0) |
MSKCC prognostic risk group, n (%) | ||
Favorable | 2 (3.2) | 0 |
Intermediate | 53 (85.5) | 17 (85.0) |
Poor | 7 (11.3) | 3 (15.0) |
IMDC prognostic risk group, n (%) | ||
Favorable | 24 (38.7) | 5 (25.0) |
Intermediate | 27 (43.5) | 13 (65.0) |
Poor | 11 (17.7) | 2 (10.0) |
Median time since diagnosis of metastatic disease (range), months | 2.5 (0.4–90.4) | 15.0 (1.6–80.4) |
Number of prior anticancer therapy lines for metastatic or locally advanced disease, n (%) | ||
0 | 62 (100.0)a | 0 |
1 | 0 | 19 (95.0) |
2 | 0 | 0 |
3 | 0 | 0 |
≥ 4 | 0 | 1 (5.0) |
PD-L1 status (≥ 1% tumor cells), n (%) | ||
Positive | 20 (32.3) | 4 (20.0) |
Negative | 21 (33.9) | 9 (45.0) |
Not evaluable | 21 (33.9) | 7 (35.0) |